scholarly journals Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population

2004 ◽  
Vol 41 (3) ◽  
pp. 201-206 ◽  
Author(s):  
P. McArdle ◽  
M. Pollock ◽  
A. Wallace ◽  
D. McMillan ◽  
J. Crooks ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigens ◽  
Prostate Specific Antigens

R75251 in Prostate Cancer Patients in Progression after First-Line Hormonal Treatment

1994 ◽  
Vol 80 (4) ◽  
pp. 276-279 ◽  
Author(s):  
Francesco Boccardo ◽  
Daniela Cannata ◽  
Domenico Guarneri ◽  
Francesco Oneto ◽  
Enrico Cortesi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Potential ◽  
Hormonal Treatment ◽  
Severe Toxicity ◽  
Advanced Prostatic Cancer ◽  
Monthly Basis ◽  
Number Of Patients ◽  
Specific Antigens ◽  
Hormone Refractory ◽  
Prostate Specific Antigens

Introduction The therapeutic potential of R75251, a ketoconazole derivative which has shown marked antitumor activity in animals and in men, was investigated in 16 patients with advanced prostatic cancer progressing after one or more lines of hormone therapy. Patients and methods Patients were given the drug at 150 mg/b.i.d. for one month. After the first month of treatment, the dose was increased to 300 mg/b.i.d. In all patients, treatment was continued until disease progression or the development of severe toxicity. Clinical and biochemical assessments were performed on days 0, 14 and 28 and then repeated on a monthly basis. Results Of the 13 evaluable patients, 12 showed stable disease by strictly employing US-NPCP criteria. However, in 3 patients a clear effect was observed on the volume of their measurable lesions. In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good. Conclusions Our results, although achieved in a small number of patients, suggest that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated.

scholarly journals Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 173
Author(s):  
Maria Adamaki ◽  
Vassilios Zoumpourlis
Keyword(s):  
Prostate Cancer ◽  
Precision Medicine ◽  
Checkpoint Inhibitors ◽  
Invasive Disease ◽  
Patient Specific ◽  
Treatment Alternative ◽  
Substantial Evidence ◽  
Significant Survival ◽  
Localized Disease ◽  
Specific Antigens

Prostate cancer (PCa) is the most frequently diagnosed type of cancer among Caucasian males over the age of 60 and is characterized by remarkable heterogeneity and clinical behavior, ranging from decades of indolence to highly lethal disease. Despite the significant progress in PCa systemic therapy, therapeutic response is usually transient, and invasive disease is associated with high mortality rates. Immunotherapy has emerged as an efficacious and non-toxic treatment alternative that perfectly fits the rationale of precision medicine, as it aims to treat patients on the basis of patient-specific, immune-targeted molecular traits, so as to achieve the maximum clinical benefit. Antibodies acting as immune checkpoint inhibitors and vaccines entailing tumor-specific antigens seem to be the most promising immunotherapeutic strategies in offering a significant survival advantage. Even though patients with localized disease and favorable prognostic characteristics seem to be the ones that markedly benefit from such interventions, there is substantial evidence to suggest that the survival benefit may also be extended to patients with more advanced disease. The identification of biomarkers that can be immunologically targeted in patients with disease progression is potentially amenable in this process and in achieving significant advances in the decision for precision treatment of PCa.

Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review

2018 ◽  
Vol 25 (4) ◽  
pp. 903-917 ◽  
Author(s):  
Neda Khalili ◽  
Mahsa Keshavarz-Fathi ◽  
Sepideh Shahkarami ◽  
Armin Hirbod-Mobarakeh ◽  
Nima Rezaei
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Monoclonal Antibodies ◽  
Advanced Prostate Cancer ◽  
Search Strategy ◽  
Specific Immunotherapy ◽  
Therapeutic Option ◽  
Grey Literature ◽  
Statistical Heterogeneity ◽  
Specific Antigens

Introduction Treatment of metastatic castration-resistant prostate cancer with conventional therapies is still not successful. Therefore, application of novel biological approaches such as immunotherapy, which appears to be more effective and less toxic, is necessary. Monoclonal antibodies against cancer specific antigens are a kind of immunotherapy that have been approved for specific types of cancer and are being investigated for prostate cancer as well. The aim of this review was to assess the effectiveness and safety of monoclonal antibodies for treatment of advanced prostate cancer. Method According to the search strategy stated in our systematic review protocol, Scopus, Medline, TRIP, CENTRAL, ProQuest, DART and OpenGrey databases were searched. Data collection and quality assessment were done independently by two authors and any disagreements between the collected data were resolved by a third author. A meta-analysis was not feasible as there was a considerable statistical heterogeneity among the trials. Hence, this review was limited to a narrative analysis of the included studies. Results We found 9756 references by applying search strategy in 4 databases of journal articles and 3 databases of grey literature. We then discarded 3957 duplicate citations using Endnote software and 5143 articles due to obvious irrelevancy of their topics in primary screening. In secondary screening of 656 fulltexts, we excluded 538 articles, and finally included 12 trials in this systematic review, updated on 23 June 2017. The overall quality of the studies was fair. In general, results of this systematic review show promising advances in the treatment of prostate cancer patients with monoclonal antibodies against prostate-specific antigens with regard to PSA/disease response. Some of the studies reported pain relief after treatment as well. Conclusion Currently, the role of immunotherapy in the treatment of advanced prostate cancer still remains debated. Although passive specific immunotherapy could be offered as a novel therapeutic option in the coming years, patients should be informed about the risks and benefits of this therapy. One of the obstacles in this review was the lack of adequate assessment of survival-related endpoints reported in the included studies. Our study provides support for further research in this field.

414 VACCINATION WITH RAD5 CARRYING A FUSION CONSTRUCT OF PROSTATE-SPECIFIC ANTIGENS GENERATES EFFECTOR T CELLS

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Felipe Rosso ◽  
Jeffrey Holzbeierlein ◽  
Peter Van Veldhuizen ◽  
Dev Karan
Keyword(s):  
T Cells ◽  
Effector T Cells ◽  
Fusion Construct ◽  
Specific Antigens ◽  
Prostate Specific Antigens

scholarly journals A novel immobilization strategy for electrochemical detection of cancer biomarkers: DNA-directed immobilization of aptamer sensors for sensitive detection of prostate specific antigens

The Analyst ◽  
2015 ◽  
Vol 140 (8) ◽  
pp. 2628-2633 ◽  
Author(s):  
Zhugen Yang ◽  
Barbara Kasprzyk-Hordern ◽  
Sean Goggins ◽  
Christopher G. Frost ◽  
Pedro Estrela
Keyword(s):  
Electrochemical Detection ◽  
Cancer Biomarkers ◽  
Dna Aptamer ◽  
Sensitive Detection ◽  
Protein Biomarker ◽  
Specific Antigens ◽  
Prostate Specific Antigens

A novel immobilization strategy of DNA aptamer sensors for sensitive detection of a protein biomarker was developed based on DNA-directed immobilization.

scholarly journals Prospective investigation of change in the prostate-specific antigens after various urologic procedures

2015 ◽  
pp. 1213 ◽  
Author(s):  
Jong Park ◽  
Seung Chol Park ◽  
Yu Seob Shin ◽  
Li Tao Zhang ◽  
Dal Sik Kim ◽  
...  
Keyword(s):  
Specific Antigens ◽  
Prostate Specific Antigens ◽  
Prospective Investigation

scholarly journals Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maryam Hosseindokht ◽  
Hamid Bakherad ◽  
Hamed Zare
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Cancer Cells ◽  
Target Therapy ◽  
Main Body ◽  
Prostate Cancer Cells ◽  
New Horizons ◽  
Large Size ◽  
Cancer Antigens ◽  
Specific Antigens

Abstract Background Prostate cancer is one of the most common cancers in men and its incidence has increased dramatically in the last decade. This increase in the detection of this type of cancer is based more on the detection of PSA or PSMA antigens as the most important specific antigens of this cancer, and this early detection has greatly helped in the more optimal treatment of patients. Main body Many methods have been proposed by researchers for early detection of prostate cancer, but most of the methods used today to detect this type of cancer have been using classical antibodies. Although classical antibodies are able to detect tumor cell markers, but instability, large size, costly and laborious production, and random immobility characteristics, causes many problems. Nanobodies or VHHs, which are derived from camel heavy chain antibodies, have special advantages and have eliminated the disadvantages of classical antibodies which makes them attractive to use in biosensors and cancer diagnostic kits. The research that has been done so far shows that the introduced nanobodies are created for the purpose of targeting, detecting and sensing prostate cancer cells with two main purposes. The first is the efficient identification of prostate cancer and the second is the elimination of cancer cells. Conclusion Research shows the use of specific nanobodies against prostate cancer antigens in the design of biosensors and target therapy will be very interesting. In this review article, these nanobodies are introduced and categorized based on their performance.

Sign in / Sign up

Export Citation Format

Share Document